Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SimuGen Ltd.

This article was originally published in Start Up

Executive Summary

SimuGen has developed an analysis system that includes a pre-packaged kit that customers can use to test their own compounds. Accompanying client management software then imports the data and sends it to SimuGen's servers for analysis. It produces a dose-response curve for every clinically significant toxicity and also ranks related compounds based on their toxicity profile, allowing medicinal chemists to evaluate potential leads. Finally, clustering analysis reveals how changes to the molecular structure could affect the toxicity profile. The product has been designed to work with relatively few biomarker genes, which simplifies the laboratory procedure and avoids platforms such as microarrays.

You may also be interested in...



Start-Up Previews (10/20080

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Making Inroads in Predictive Toxicology," features profiles of Cellumen, GliaGen, Horizon Discovery and SimuGen. Plus these Start-Ups Across Health Care: Acacia Pharma, InspireMD, MicroTransponder and Quotient Diagnostics.

GliaGen LLC

When cells are subject to stress, they react with change at the ribosomal level, altering the process of translation and the resulting protein products. Tapping into that insight is the basic premise behind GliaGen, which is developing novel screening technologies that represent a unique, previously unknown methodology for measuring cellular stress and death. The firm's translation regulatory expression system helps assess drug candidates for toxicity and safety risks early in the lead identification and drug discovery processes.

Horizon Discovery Ltd.

Horizon Discovery is creating human isogenic cell lines aimed at making drug discovery faster and more effective, potentially leading to the creation of more targeted or personalized medicines. Their virus-based technique, known as GENESIS, can precisely engineer disease-causing and patient-specific single, double, and triple genetic mutations into normal human cells. GENESIS underpins Horizon's rapidly growing portfolio of X-MAN (Mutant And Normal) cell-line pairs that may help pharmaceutical researchers assess the likely patient response to a potential drug candidate by defining the potential patient responder demographic much earlier in the development time line.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC091669

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel